Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Oct 14;333(7572):794-7.
doi: 10.1136/bmj.333.7572.794.

ABC of obesity. Management: part II--drugs

Mike Lean  1 , Nick Finer
Affiliations
Review

ABC of obesity. Management: part II--drugs

Mike Lean et al. BMJ. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Obese patients are at increased risk from cardiovascular disease: it is imperative that risk factors are treated early and optimally. Effective treatment to prevent the underlying cause (body fat accumulation) would make better clinical and economic sense and is now accepted as a reasonable target for drug development
Figure 2
Figure 2
Effects on weight loss of sibutramine with or without some degree of lifestyle modification (adapted from Wadden et al. N Engl J Med 2005;353: 2111-20)
Figure 3
Figure 3
Proportion of study participants achieving 5-10% weight loss in one year, according to drug taken (data from combined datasets of 1 year phase 3 trials of three obesity drugs including rimonabant (adapted from Finer N, see Further Reading box)
Figure 4
Figure 4
Weight loss over first year of treatment with rimonabant (combined with lifestyle modification) is maintained in year 2 if drug is continued. Weight regain occurs if drug is withdrawn even if lifestyle modification is continued (adapted from Pi-Sunyer et al. JAMA 2006;295: 761-75)
Figure 5
Figure 5
Recombinant leptin given once or twice daily in addition to lifestyle advice on weight loss over 12 weeks in obese subjects with normal plasma leptin concentration shows no benefit over placebo. (Adapted from Zelissen et al. Diabetes Obes Metab 2005;7: 755-61)
See this image and copyright information in PMC

References

    1. Finer N. Does pharmacologically-induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk. Eur Heart J Supplements 2005;7(suppl): L32-8.
    1. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005;4(6): 1083-95. - PubMed
    1. Pagotto U, Vicennati V, Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med 2005;37: 270-5. - PubMed
    1. Small CJ, Parkinson JR, Bloom SR. Novel therapeutic targets for appetite regulation. Curr Opinion Invest Drugs 2005;6: 369-72. - PubMed
    1. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs 2004;64: 2845-64. - PubMed

Substances